Cancer Genetics to Attend ASCO Annual Meeting

Cancer Genetics to Attend ASCO Annual Meeting

RUTHERFORD, N.J.--(BUSINESS WIRE)-- Cancer Genetics, Inc. (OTCQB: CGIX) ("CGI" or the "Company"), a leader in oncology-focused personalized medicine, will attend for the first time the 2013 American Society of Clinical Oncology ("ASCO") Annual Meeting on May 31-June 4, 2013 at McCormick Place in Chicago. CGI will be at stand number 19120 during the event.

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties to discuss challenges and developments in cancer care and research.

Fitting with the theme of this year's meeting, "Building Bridges to Conquer Cancer," CGI has established research collaborations with premier institutions including Memorial Sloan-Kettering Cancer Center, National Cancer Institute, Cleveland Clinic and Mayo Clinic. These and other efforts have resulted in the Company's commercial launch of multiple proprietary tests for the diagnosis and treatment management of hematological and urogenital cancers.

CGI diagnostic tests include MatBA®, based on proven genomic data for the clinical management of hematological cancers, and UroGenRA™, designed for kidney cancer diagnosis and subtyping.

In addition to presenting these proprietary tests to healthcare professionals, CGI plans to meet with biopharmas as well. CGI's Select One™ program, launched in early 2012 to serve the clinical trial needs of biopharmas, has shown constant growth since its inception. The Company looks forward to creating new opportunities at the ASCO meeting.

To learn more about the 2013 ASCO Annual Meeting, visit http://chicago2013.asco.org.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and services some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers.

We also provide a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State.

CGI has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended March 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

Investor Relations
RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107
jon@redchip.com

KEYWORDS: United States North America Illinois New Jersey

INDUSTRY KEYWORDS:

The article Cancer Genetics to Attend ASCO Annual Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.